Alirocumab

Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...


A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin...


Two anti-proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies, Alirocumab and Evolocumab, have been approved for the treatment...


The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving...


Alirocumab ( Praluent ), a monoclonal antibody that inhibits proprotein convertase subtilisin – kexin type 9 ( PCSK9 ), has...


A study has compared the efficacy [ low-density lipoprotein cholesterol ( LDL-C ) lowering ] and safety of Alirocumab (...


The FDA ( Food and Drug Administration ) has approved Praluent ( Alirocumab ) injection, the first cholesterol-lowering treatment approved...


Despite current standard-of-care, many patients at high cardiovascular disease ( CVD ) risk still have elevated low-density lipoprotein cholesterol (...


Inhibition of proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) has been intensively studied to lower low-density lipoprotein cholesterol (...


Alirocumab ( Praluent ) lowers cholesterol in patients with heterozygous familial hypercholesterolemia to levels unreachable with statins alone, according to...


Efficacy and safety of Alirocumab were compared with Ezetimibe ( Ezetrol, Zetia ) in hypercholesterolemic patients at moderate cardiovascular risk...


Results from four Phase 3 ODYSSEY trials of Alirocumab in people with hypercholesterolemia. Alirocumab is an investigational monoclonal antibody...


Sanofi and Regeneron Pharmaceuticals have announced that the Phase 3 ODYSSEY MONO trial with Alirocumab, an investigational monoclonal antibody targeting...